Results 31 to 40 of about 9,615 (165)

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

open access: yesHaematologica, 2017
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients.
Jennifer R. Brown   +26 more
doaj   +1 more source

RETRACTED ARTICLE: Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway

open access: yesCell Death and Disease, 2023
Ibrutinib is a drug that inhibits the protein Burton’s tyrosine kinase and thereby the nuclear translocation of Nrf2, which played a key role in mediating the activation of antioxidants during stress conditions and ferroptosis resistance.
Jin-Feng Zhu   +8 more
doaj   +1 more source

Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia

open access: yesCase Reports in Hematology, 2021
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton’s tyrosine kinase, and it is an approved treatment for several mature B-cell malignancies including chronic lymphocytic leukaemia (CLL).
Sara Kristina Viberg Tjønnfjord   +3 more
doaj   +1 more source

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

open access: yesJournal for ImmunoTherapy of Cancer, 2023
Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy.
Li Zhang   +28 more
doaj   +1 more source

Extrahepatic metabolism of ibrutinib [PDF]

open access: yes, 2021
Ibrutinib is a first-in-class Bruton's kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed.
Rood, Johannes J M   +15 more
core  

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

open access: yeseJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi   +9 more
doaj   +1 more source

Results from a phase 1b/2 study of ibrutinib combination therapy in advanced urothelial carcinoma [PDF]

open access: yes, 2023
Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease.
Jones, Robert J   +43 more
core   +1 more source

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

open access: yesBlood Advances, 2018
: The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially.
Jimmy Lee   +14 more
doaj   +1 more source

Dual Mechanism of Severe Bleeding Diathesis in a Patient with CLL: Acquired Von Willebrand Syndrome and Ibrutinib - Mediated Platelets Dysfunction [PDF]

open access: yes, 2020
We here report an informative case of severe bleeding diathesis in a patient with Chronic Lymphocytic Leukaemia (CLL), due to Acquired Von Willebrand Syndrome (AVWS) and impaired platelets aggregation under the treatment with Ibrutinib. Keywords:
Novak, U, Bürki, S
core   +1 more source

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

open access: yesBlood Advances, 2018
: Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses.
James I. Barnes   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy